GlassScriptPhysician profile
Shawnee D Weir
NPI 1245208529
$1,593.17
in general payments reported to CMS, 2019-2025
24 companies · none reported in 2025
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $403 · 2020: $689 · 2021: $124 · 2023: $359 · 2024: $18.41.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $344 · Education: $33.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $344.05 |
| Education | $33.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mannkind Corporation | $288.86 | 2019-2021 | |
| Xeris Pharmaceuticals, INC. | $195.26 | 2020-2024 | Recorlev |
| Janssen Pharmaceuticals, INC | $180.81 | 2019-2020 | |
| Novo Nordisk INC | $178.52 | 2019-2023 | Wegovy |
| Lilly USA, LLC | $158.26 | 2020-2023 | Mounjaro |
| Abbott Laboratories | $114.37 | 2020-2023 | Freestyle Libre 3 |
| Ibsa Pharma INC. | $60.26 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $44.56 | 2019-2023 | Jardiance |
| Abbvie INC. | $43.30 | 2020-2023 | Synthroid |
| Amgen INC. | $42.02 | 2019-2023 | Prolia, Evenity |
| Dexcom, INC. | $32.48 | 2019-2023 | Dexcom G6 Transmitter |
| Gilead Sciences, INC. | $31.47 | 2019 | |
| Acella Pharmaceuticals, LLC | $28.72 | 2019-2020 | |
| Senseonics, Incorporated | $27.00 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $24.52 | 2019-2020 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ascendis Pharma Endocrinology INC | $22.97 | 2023 | |
| Companion Medical, INC. | $19.66 | 2019 | |
| Endo Pharmaceuticals INC. | $16.62 | 2023 | Aveed |
| Nestle Healthcare Nutrition INC. | $16.05 | 2020 | |
| Insulet Corporation | $15.53 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $14.50 | 2021 | |
| Medtronic Minimed, INC. | $13.17 | 2019 | |
| Sanofi-Aventis U.S. LLC | $12.57 | 2020 | |
| Horizon Therapeutics Plc | $11.69 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shawnee Weir listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.